BNGO
Bionano Genomics, Inc.
$1.16
-2.52%
$13.3M
No data for this timeframe.
Vol
Market Cap$13.3M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders15 funds
Inst. Value$244.0K
Inst. Activity2 buys / 2 sells
SEC Reports2
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Alka Chaubey, Ph.D., resigned as Chief Medical Officer of Bionano Genomics, effective July 5, 2026. The filing provides
8-K — Impact 4/10
Jun 3, 2026
Insider
Adamchak Mark surrendered for taxes 7 shares
Principal Accounting Officer @ $1.30 ($9.10)
Jun 3, 2026
Insider
Chaubey Alka surrendered for taxes 24 shares
CHIEF MEDICAL OFFICER @ $1.30 ($31.20)
Jun 3, 2026
Insider
OLDAKOWSKI MARK surrendered for taxes 27 shares
CHIEF OPERATING OFFICER @ $1.30 ($35.10)
May 28, 2026
SEC
Bionano Genomics fully retired its $20M Senior Secured Convertible Debentures using cash on hand, eliminating all secure
8-K — Impact 5/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
48,700 shares ($57.0K)
Inst.
GROUP ONE TRADING LLC — TRIM
957 shares ($1.1K)
May 28, 2026
other
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
<p>SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announc
Price Targets
$5.00
+331.0% upside
Strong Buy
Current $1.16
Low $4.00
Median $5.00
High $6.00
2 analysts
$4.00
$6.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.67 ▲ +15.7% | $-0.67 — $-0.67 | 66% YoY | 1 |
| Next Q | $-0.42 ▲ +23.6% | $-0.42 — $-0.42 | 74% YoY | 1 |
| Current FY | $-2.71 ▼ -8.8% | $-2.71 — $-2.71 | 44% YoY | 1 |
| Next FY | $-1.11 ▲ +9.0% | $-1.11 — $-1.11 | 59% YoY | 1 |
Latest Reports
BEARISH
8-K
4/10
Alka Chaubey, Ph.D., resigned as Chief Medical Officer of Bionano Genomics, effective July 5, 2026. The filing provides
Jun 5, 2026
BULLISH
8-K
5/10
Bionano Genomics fully retired its $20M Senior Secured Convertible Debentures using cash on hand, eliminating all secure
May 28, 2026
BEARISH
Press
6/10
Bionano Genomics reported Q4 and full-year 2025 results with declining revenue and net losses, though gross margins and
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $79.7K | — |
| VANGUARD FIDUCIARY TRUST CO | $60.3K | — |
| RENAISSANCE TECHNOLOGIES LLC | $57.0K | ADD |
| PRUDENTIAL FINANCIAL INC | $32.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Adamchak Mark | F | $9.10 |
| Jun 3, 2026 | Chaubey Alka | F | $31.20 |
| Jun 3, 2026 | OLDAKOWSKI MARK | F | $35.10 |
| Jun 3, 2026 | Dixon Jonathan | F | $31.20 |
| May 14, 2026 | BARKER DAVID | A | $0.00 |
15 institutional holders with $244.0K total value (208,525 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 11 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 68,109 | $79.7K | 32.7% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 51,578 | $60.3K | 24.7% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 48,700 | $57.0K | 23.4% | ADD +31.6% |
| 5 | PRUDENTIAL FINANCIAL INC | 28,000 | $32.8K | 13.4% | — |
| 6 | BlackRock, Inc. | 9,937 | $11.6K | 4.8% | — |
| 7 | GROUP ONE TRADING LLC | 957 | $1.1K | 0.5% | TRIM -27.1% |
| 8 | MORGAN STANLEY | 927 | $1.1K | 0.4% | TRIM -58.3% |
| 9 | Vanguard Global Advisers, LLC | 173 | $202.00 | 0.1% | — |
| 10 | WELLS FARGO & COMPANY/MN | 113 | $132.00 | 0.1% | TRIM -73.5% |
| 11 | Allworth Financial LP | 6 | $8.00 | 0.0% | — |
| 12 | FMR LLC | 6 | $7.00 | 0.0% | — |
| 13 | TD Waterhouse Canada Inc. | 5 | $6.00 | 0.0% | ADD +25.0% |
| 14 | NATIONAL BANK OF CANADA /FI/ | 2 | $2.00 | 0.0% | — |
| 15 | CITIGROUP INC | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 37,000 | 48,700 | +31.6% | $57.0K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 1,312 | 957 | -27.1% | $1.1K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 2,224 | 927 | -58.3% | $1.1K | 2026-Q1 |
| TD Waterhouse Canada Inc. | ADD | 4 | 5 | +25.0% | $6.00 | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 50,459 | 82,307 | +63.1% | $125.9K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 6,208 | 2,224 | -64.2% | $3.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 113 | 30 | -73.5% | $46.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 2,670 | 63,876 | +2292.4% | $109.2K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 11,655 | 6,208 | -46.7% | $10.6K | 2025-Q3 |
10 unique insiders with 14 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Adamchak Mark | Principal Accounting Officer | TAX W/H | 7 | $1.30 | $9.10 |
| Jun 3, 2026 | Chaubey Alka | CHIEF MEDICAL OFFICER | TAX W/H | 24 | $1.30 | $31.20 |
| Jun 3, 2026 | OLDAKOWSKI MARK | CHIEF OPERATING OFFICER | TAX W/H | 27 | $1.30 | $35.10 |
| Jun 3, 2026 | Dixon Jonathan V. | GENERAL COUNSEL | TAX W/H | 24 | $1.30 | $31.20 |
| May 14, 2026 | BARKER DAVID L | Director | AWARD | 9,149 | — | — |
| May 14, 2026 | TWOMEY CHRISTOPHER J | Director | AWARD | 9,149 | — | — |
| May 14, 2026 | Vuori Kristiina MD | Director | AWARD | 9,149 | — | — |
| May 14, 2026 | Linney Yvonne | Director | AWARD | 9,149 | — | — |
| May 14, 2026 | Rajkovic Aleksandar | Director | AWARD | 9,149 | — | — |
| Feb 2, 2026 | Dixon Jonathan V. | GENERAL COUNSEL | AWARD | 26,117 | — | — |
| Feb 2, 2026 | Holmlin R. Erik | PRESIDENT AND CEO | AWARD | 69,484 | — | — |
| Feb 2, 2026 | Adamchak Mark | Principal Accounting Officer | AWARD | 10,890 | — | — |
| Feb 2, 2026 | Chaubey Alka | CHIEF MEDICAL OFFICER | AWARD | 27,737 | — | — |
| Feb 2, 2026 | OLDAKOWSKI MARK | CHIEF OPERATING OFFICER | AWARD | 27,737 | — | — |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 4.5/10.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.00 mean target
+331.0% upside
Strong Buy (3.00)
$4.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $1.16 |
| Target Low | $4.00 |
| Target Mean | $5.00 |
| Target Median | $5.00 |
| Target High | $6.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.67 | $-0.67 | $-0.67 | 66.3% | +15.7% | 1↑ 0↓ | $0.0B | 11.0% | 1 |
| Next Q 2026-09-30 |
$-0.42 | $-0.42 | $-0.42 | 73.6% | +23.6% | 1↑ 0↓ | $0.0B | 16.4% | 1 |
| Current FY 2026-12-31 |
$-2.71 | $-2.71 | $-2.71 | 43.8% | -8.8% | 1↑ 0↓ | $0.0B | 12.7% | 1 |
| Next FY 2027-12-31 |
$-1.11 | $-1.11 | $-1.11 | 59.0% | +9.0% | 1↑ 0↓ | $0.0B | 34.7% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.670 | |
| 7d ago | $-0.795 | +0.125 |
| 30d ago | $-0.795 | +0.125 |
| 60d ago | $-0.775 | +0.105 |
| 90d ago | $-0.740 | +0.070 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
other
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
<p>SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all out
May 13, 2026
earnings
Bionano Reports First Quarter 2026 Results and Provides a Business Update
Conference call today, May 13, 2026, at 4:30 PM ET <pre>Conference call today, May 13, 2026, at 4:30 PM ET</pre>
May 13, 2026
earnings_calendar
BNGO Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
leadership
Bionano Announces Leadership Transition
<p align="left">SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman o
Mar 30, 2026
earnings_calendar
BNGO Q4 2025 Earnings After Market Close — 2026-03-30
Mar 23, 2026
earnings
Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
Conference call today, March 23, 2026, at 4:30 PM ET <pre>Conference call today, March 23, 2026, at 4:30 PM ET</pre>
Mar 23, 2026
short_volume
Short Volume: BNGO — 62.3% short (0.6M / 1.0M)
Short: 619,848 | Exempt: 5,183 | TRF Vol: 994,618 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Mar 9, 2026
earnings
Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
<p>SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live